Xience™ Family of Drug Eluting Stents

The world's leading drug eluting stents (DES)


Discover the unique design and acute performance of XIENCE™ in this short video.

Unique Design

Acute Performance

Lasting Outcomes


Innovative Stent Design

Anti-Thrombotic Fluoropolymer1

Market-Leading Everolimus2


XIENCE™ Stent showed significant improvement 2 weeks after PCI3:

  • Better Strut Coverage (p<0.01)
  • Less Thrombus (p=0.03)
  • Larger Lumen Area (p=0.048)

Post-PCI

2 Weeks Post-PCI


Definite stent thrombosis with XIENCE™ stent compared to BMS in STEMI patients at 30 days (0.4% vs 1.6%, p=0.02)


Bifurcations lesions5

Excellent early outcomes in bifurcations
0.0% Def. ST at 30 days

Calcified lesions6

Excellent early outcomes in
calcified lesions
0.0% Def. ST at 30 days

Long lesions7

Excellent early outcomes in long lesions
0.3% Def. ST at 30 days


XIENCE™ Stent has significantly lower rates of acute and early stent thrombosis than Synergy and Resolute‡8,9

Definite stent thrombosis at 24 hours8

Definite stent thrombosis at 30 days9


Lasting Outcomes

XIENCE™ Stent has the largest body of DAPT patient evidence10

CONSISTENTLY LOW STENT THROMBOSIS (ST) RATES WITH 1-MONTH DAPT12

≤0.1% Definite ST rate at 12 months for 3 short DAPT analyses14


XIENCE™ STENT IS SUPPORTED BY UNMATCHED REAL-WORLD PATIENT EVIDENCE, CONSISTENTLY DELIVERING OUTSTANDING SHORT-AND-LONG-TERM OUTCOMES.15,16


Abbott’s Coronary Intervention Portfolio

 

 

™ Indicates a trademark of the Abbott Group of Companies.
 Indicates a third-party trademark, which is property of its respective owner.

References: 1. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:Suppl B – TCT-291. 2. Data on file at Abbott. 3. Morino Y, et al. Cardiovasc Interv and Ther. 2019;34:14-24. 4. Sabate M, et al. Lancet. 2012;380:1482-1490. 5. Dzivak V, Catheter Cardiovasc Interv. 2013;82(3):E163-E172. 6. Onuma Y, et al. Catheter Cardiovasc Interv. 2010;76:634–642. 7. Hong S, et al. Am Coll Cardiol Intv 2016;9:1438–1446. 8. Zanchin, C. et al. J Am Coll Cardiol Intv. 2019;12(17):1665-1675. 9. Serruys P, et al. N Engl J Med. 2010;363:136-146. 10. Généreux P, et al. Circ Cardiovasc Interv. 2015;8(5):1-16; Natsuaki et al., Cardiovasc Interv and Ther. 2016. 31:196–209; Watanabe H, et al. JAMA. 2019;321(24):2414-2427; Hahn J, et al. ACC 2019 – SMART CHOICE; Valgimigli M, et al. Circulation. 2012;125:2015-2026; Gilard M, et al. J Am Coll Cardiol 2015;65:777-786; Hong SJ, et al. J Am Coll Cardiol Intv. 2016;9:1438–1446. Gwon HC, et al. ACC 2011 - EXCELLENT. 11. Généreux P, et al. Circ Cardiovasc Interv. 2015;8(5):1-16; Natsuaki et al., Cardiovasc Interv and Ther. 2016. 31:196–209 - STOPDAPT; Watanabe H, et al. JAMA. 2019;321(24):2414-2427 – STOPDAPT 2; Hahn J, et al. ACC 2019 – SMART CHOICE; Watanabe H, et al. TCT 2019 – STOPDAPT 2 – HBR SubAnalysis; Varenne O, et al. 2018. Lancet. 391:41-50 – SENIOR; Kirtane A, et al. TCT 2019 – EVOLVE Short DAPT. Windecker S, et al. TCT 2019 – OnyxOne; Postma W, et al. 2019. Cather Cardiovasc Inter. 1-5 – DAPT STEMI. 12. Natsuaki et al., Cardiovasc Interv and Ther. 2016. 31:196–209. Watanabe H, et al. JAMA. 2019;321(24):2414-2427. Watanabe H, et al. Cardiovasc Interv and Ther 2020. doi.org/10.1007/s12928-020-00651-9. 13. Baron S, et al. J Am Coll Cardiol. 2017;70:3113-3122. 14. Kufner S, et al. Circulation. 2019:139(3):325-333. Shiomi H, et al. J Am Coll Cardiol Interv. 2019;12:637-647. 15. Data on file at Abbott. 15,000,000 implants number is based on data of DES implants through Q1, 2020. 
16. Zanchin, C. et al. J Am Coll Cardiol Intv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. J Am Coll Cardiol Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. 17. Kufner S, et al. Circulation. 2019;139(3):325-333.

Date of preparation: May 2021. SFM_ABO1755.

MAT-2105209 v1.0